If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A
PDUFA Target Action Date is March 31, 2023
SAN RAFAEL, Calif., Oct. 12, 2022 /PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S. Fo.
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval08-Jun-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the.